Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drug Safety
Erschienen in: Drug Safety 5/2001

01.04.2001 | Review Article

Management of Chemotherapy-Induced Adverse Effects in the Treatment of Colorectal Cancer

verfasst von: Dr Frank G.A. Jansman, Dirk T. Sleijfer, Jacques C. de Graaf, Jules L.L.M. Coenen, Jacobus R.B.J. Brouwers

Erschienen in: Drug Safety | Ausgabe 5/2001

Einloggen, um Zugang zu erhalten

Abstract

The anticancer agents fluorouracil, raltitrexed, irinotecan and oxaliplatin show limited efficacy in the treatment of colorectal cancer and may be associated with substantial toxicity. Therefore, the prevention and reduction of chemotherapy-induced adverse effects is of major significance, in accordance with the increasing concern for the quality of life of patients with cancer.
Therapeutic drug monitoring of fluorouracil and chronomodulation of fluorouracil and oxaliplatin, have been effective in reducing the incidence and gravity of adverse effects in several clinical trials. However, these concepts have not been implemented in clinical practice yet. At the present time, dose adaptation and supportive measures are the main tools for toxicity control in the treatment of colorectal cancer. In this review, supportive measures for alleviation of the adverse effects of fluorouracil, raltitrexed, irinotecan and oxaliplatin, respectively, are described, based on study results.
The main adverse effects of these agents are myelosuppression, oral mucositis, diarrhoea, acute cholinergic syndrome, nausea and emesis, neurotoxicity, hand-foot syndrome and other cutaneous adverse effects, ocular toxicity, cardiotoxicity, small bowel toxicity, asthenia, elevated liver transaminase levels and alopecia. The incidence and gravity of these adverse effects are more or less related to the agent and administration schedule involved. The supportive measures and recommendations include the use of specific drugs, alterations of administration schedule and several nonpharmacological methods. In addition, guidelines for dosage adjustments when toxicity occurs are presented.
For optimal management of adverse effects, patients should be considered individually, while patients, nurses and physicians should cooperate to identify and treat adverse effects in an early stage of their development.
Literatur
1.
Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–8PubMedCrossRef
2.
Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321–6PubMed
3.
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939–44
4.
Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000; 321: 531–5
5.
Sobrero A, Kerr D, Glimelius B, et al. New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer 2000; 36: 559–66PubMedCrossRef
6.
Poon MA, O’Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407–17PubMed
7.
Poon MA, O’Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967–72PubMed
8.
Machover D, Goldschmidt E, Chollet P, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986; 4: 685–96PubMed
9.
Petrioli R, Lorenzi M, Aquino A, et al. Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. Eur J Cancer 1995; 31A: 2105–8PubMedCrossRef
10.
O’Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo clinic/North Central Cancer Treatment Group Study. Cancer 1989; 63: 1026–30PubMedCrossRef
11.
De Gramont A, Bosset J, Milan C, et al. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808–15PubMed
12.
Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303–11PubMed
13.
Buroker TR, O’Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14–20PubMed
14.
Fried G, Tsalik M, Stein M, et al. 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. Cancer Chemother Pharmacol 1995; 35: 437–40PubMedCrossRef
15.
Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previous untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559–65PubMed
16.
Nobile MT, Rosso R, Sertoli MR, et al. Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 1992; 28A: 1823–7CrossRef
17.
Petrelli N, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419–26PubMed
18.
Jäger E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. J Clin Oncol 1996; 14: 2274–9PubMed
19.
De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988; 24: 1499–1503PubMedCrossRef
20.
Johnson PWM, Thompson PI, Seymour MT, et al. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal carcinoma. Br J Cancer 1991; 64: 603–5PubMedCrossRef
21.
Ardalan B, Chua L, Tian EM, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991; 9: 625–30PubMed
22.
Köhne CH, Wilke H, Hecker H, et al. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 1995; 6: 461–6PubMed
23.
Yang TS, Hsu KC, Chiang JM, et al. A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. Cancer 1999; 85: 1925–30PubMed
24.
Köhne CH, Schöffski P, Wilke H, et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998; 16: 418–26PubMed
25.
Weh HJ, Dierlamm J, Hossfeld DK. Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in previously untreated patients with metastatic colorectal carcinoma. Eur J Cancer 1994; 30A: 890–1PubMedCrossRef
26.
Chiara S, Nobile MT, Barzacchi C, et al. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 1997; 33: 967–9PubMedCrossRef
27.
Leichman CG, Leichman L, Spears CP, et al. Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 1993; 85: 41–4PubMedCrossRef
28.
Zalcberg JR, Cunningham D, Van Cutsem E, et al. ZD1694: A novel thymidylate sunthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996; 14: 716–21PubMed
29.
Cunningham D, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing ‘Tomudex’ (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. Ann Oncol 1996; 7(9): 961–5PubMedCrossRef
30.
Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16: 2943–52PubMed
31.
Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85: 786–95PubMedCrossRef
32.
Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128–35PubMed
33.
Rougier P, Van Cutsem E, Bajetta E, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407–12PubMedCrossRef
34.
Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997: 251–60
35.
Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–18PubMedCrossRef
36.
Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-Fluorouracil (5-FU). Eur J Cancer 1999; 35: 54–9PubMedCrossRef
37.
Tsavaris N, Ziras N, Kosmas C, et al. Two different schedules of irinotecan (CPT-11) administration in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil (5-FU)-leucovorin(FA) combination chemotherapy. Preliminary results of a randomized study [abstract 998]. Proc Am Soc Clin Oncol 1999; 18: 260a
38.
Bécouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998; 8: 2739–44
39.
Machover D, Diaz-Rubio E, De Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95–8PubMedCrossRef
40.
Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 9: 105–8PubMedCrossRef
41.
Van Cutsem E, Pozzo C, Starkhammer H, et al. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol 1998; 9: 1199–204PubMedCrossRef
42.
Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer 1999; 35: 1343–7PubMedCrossRef
43.
Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–7PubMedCrossRef
44.
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905–14PubMedCrossRef
45.
De Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214–9PubMedCrossRef
46.
Andre T, Louvet C, Raymond E, et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9: 1251–3PubMedCrossRef
47.
Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560–8PubMed
48.
Maindrault-Goebel F, louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999; 35: 1338–42PubMedCrossRef
49.
Brienza S, Bensmaïne MA, Soulié P, et al. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU±FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. Ann Oncol 1999; 10: 1311–6PubMedCrossRef
50.
Janinis J, Papakostas P, Samelis G, et al. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol 2000; 11: 163–7PubMedCrossRef
51.
De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47PubMed
52.
Scheithauser W, Kornek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 1999; 17: 902–6
53.
Kemeny NE, Ron IG. Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol 1999; 26: 524–35PubMed
54.
Haller G. Waiting for the definitive trial of hepatic arterial chemotherapy for colorectal cancer. J Clin Oncol 2000; 18: 239–42PubMed
55.
Jansman FGA, Sleijfer DT, Coenen JLLM, et al. Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf 2000; 23: 255–78PubMedCrossRef
56.
Santini J, Milano G, Thyss A, et al. 5-FU therapeutic drug monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989; 59: 287–90PubMedCrossRef
57.
Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998; 16: 1470–8PubMed
58.
Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998; 4: 2039–45PubMed
59.
Metzger G, Massari C, Etienne MC, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin Pharmacol Ther 1994; 56: 190–201PubMedCrossRef
60.
Bochicchio AM, Galasso R, Ignomirelli O, et al. Complete reversibility of mucositis and diarrhea induced by 5-fluorouracil in continuous infusion and l-leucovorin by using a chronomodulated schedule in advanced gastrointestinal cancer patients [abstract 1067]. Proc Am Soc Clin Oncol 1999; 18: 278a
61.
Caussanel JP, Lévi F, Brienza S, et al. Phase I trial of 5-day continuous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046–50PubMedCrossRef
62.
Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537–41
63.
AHFS Drug Information 2000. Bethesda (MD): American Society of Health-System Pharmacists, Inc., 2000: 933–8
64.
Tomudex (Raltitrexed). Summary of product characteristics. Ridderkerk: Zeneca BV, 1997
65.
CPT-11 (Irinotecan HCl). Summary of product characteristics. Amstelveen: Rhone Poulenc Rorer, 1996
66.
Eloxatin (Oxaliplatin). Summary of product characteristics. Maassluis: Sanofi Synthelabo, 1999
67.
Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333–55PubMed
68.
Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 1999; 57: 293–308PubMedCrossRef
69.
American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471–2508
70.
American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957–60
71.
American Society of Clinical Oncology. 1997 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1997; 15: 3288
72.
American Society of Clinical Oncology. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558–85
73.
Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer 1999; 85: 2103–13PubMedCrossRef
74.
Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol 1998; 25: 538–51PubMed
75.
Verdi CJ. Cancer therapy and oral mucositis. An appraisal of drug prophylaxis. Drug Saf 1993; 9: 185–95PubMedCrossRef
76.
Dodd MJ, Larson PJ, Dibble SL, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996; 23: 921–7PubMed
77.
Rocke LK, Loprinzi CL, Lee KL, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993; 72: 2234–8PubMedCrossRef
78.
Pourreau-Schneider N, Soudry M, Franquin JC, et al. Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fluorouracil: a preliminary report. J Natl Cancer Inst 1992; 84: 358–9PubMedCrossRef
79.
Cascinu S, Fedeli A, Fedelli SL, et al. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer 1994; 30B: 234–6
80.
Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of 5-fluorouracil-induced mucositis by oral cryotherapy. J Clin Oncol 1991; 9: 449–52PubMed
81.
Milles SS, Muggia AL, Spiro HM. Colonic histologic changes induced by 5-fluorouracil. Gastroenterology 1962; 43: 391–9
82.
Wadler S, Benson III AB, Engelking C, et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998; 16: 3169–78PubMed
83.
Gandia D, Abigerges D, Armand JP, et al. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 1993; 11: 196–7PubMed
84.
Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998; 16: 2745–51PubMed
85.
Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacological studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210–21PubMed
86.
Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 446–9PubMedCrossRef
87.
Savarese D, Al-Zoubi A, Boucher J. Glutamine for irinotecan diarrhea. J Clin Oncol 2000; 18: 450–1PubMed
88.
Lenfers BHM, Loeffler TM, Droege CM, et al. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999; 10: 1251–3PubMedCrossRef
89.
Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 1998; 9: 811–9
90.
Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103–9PubMed
91.
Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999; 4: 191–6PubMed
92.
National Comprehensive Cancer Network Antiemesis Practice Guidelines, Vol. 2. NCCN proceedings. Oncology 1997; 11: 57–89
93.
Catimel G, Chabot GG, Guastalla JP, et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995; 6: 133–40PubMed
94.
Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136–47PubMed
95.
Levi F, Metzger G, Massari C, et al. Oxaliplatin. Pharmacokinetics and chronopharmacological aspects. Clin Pharmacokin 2000; 38: 1–21CrossRef
96.
Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053–71PubMedCrossRef
97.
Brienza S, Vignoud J, Itzhaki M, et al. Oxaliplatin (L-OHP): global safety in 682 patients (pts) [abstract]. Proc Am Soc Clin Oncol 1995; 14: A513
98.
Vukelja SJ, Lombardo FA, James WD, et al. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989; 111: 688–9PubMed
99.
Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8: 57–63PubMedCrossRef
100.
Jucgla A, Sais G. Hand-foot syndrome. J Clin Oncol 1997; 15: 3164PubMed
101.
Mortimer JE, Anderson I. Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemother Pharmacol 1990; 26: 449–52PubMedCrossRef
102.
Al-Tweigeri T, Nabholtz JM, Mackey JR. Ocular toxicity and cancer chemotherapy. A review. Cancer 1996; 78: 1359–73PubMedCrossRef
103.
Loprinzi CL, Wender DB, Veeder MH, et al. Inhibition of 5-fluorouracil-induced ocular irritation by ocular ice packs. Cancer 1994; 74: 945–8PubMedCrossRef
104.
Meyer CC, Calis KA, Burke LB, et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997; 17: 729–36PubMed
105.
De Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795–801PubMed
106.
Becker K, Erckenbrecht JF, Häussinger D, et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999; 57: 475–84PubMedCrossRef
107.
108.
Fata F, Ron IG, Kemeny N, et al. 5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 1999; 86: 1129–34PubMedCrossRef
109.
Zalcberg J, Kerr D, Seymour L, et al. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Eur J Cancer 1998; 34: 1871–5PubMedCrossRef
110.
Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokin 1997; 33: 245–59CrossRef
111.
Gunasekara NS, Faulds D. Raltitrexed: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1998; 55: 423–35PubMedCrossRef
112.
Katsimbri P, Bamias A, Pavlidis N. Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer 2000; 36: 766–71PubMedCrossRef
113.
Schmoll HJ, Buchele T, Grothey A, et al. Where do we stand with 5-fluorouracil? Semin Oncol 1999; 26: 589–605PubMed
Metadaten
Titel
Management of Chemotherapy-Induced Adverse Effects in the Treatment of Colorectal Cancer
verfasst von
Dr Frank G.A. Jansman
Dirk T. Sleijfer
Jacques C. de Graaf
Jules L.L.M. Coenen
Jacobus R.B.J. Brouwers
Publikationsdatum
01.04.2001
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 5/2001
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124050-00002

Weitere Artikel der Ausgabe 5/2001

Drug Safety 5/2001 Zur Ausgabe

Review Article

Tolerability of Treatments for Viral Hepatitis

Leading Article

Evaluation of Drug-Induced QT Interval Prolongation

Review Article

Visual Field Defects and Other Ophthalmological Disturbances Associated with Vigabatrin

Review Article

Skin Reactions to Inhaled Corticosteroids